ECSP20084864A - Anticuerpos biespecíficos contra dll3-cd3 - Google Patents
Anticuerpos biespecíficos contra dll3-cd3Info
- Publication number
- ECSP20084864A ECSP20084864A ECSENADI202084864A ECDI202084864A ECSP20084864A EC SP20084864 A ECSP20084864 A EC SP20084864A EC SENADI202084864 A ECSENADI202084864 A EC SENADI202084864A EC DI202084864 A ECDI202084864 A EC DI202084864A EC SP20084864 A ECSP20084864 A EC SP20084864A
- Authority
- EC
- Ecuador
- Prior art keywords
- antibodies against
- specific antibodies
- against dll3
- dll3
- relates
- Prior art date
Links
- 102100036466 Delta-like protein 3 Human genes 0.000 abstract 1
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940127276 delta-like ligand 3 Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación se refiere a anticuerpos biespecíficos contra DLL3/CD3, caracterizados por sus secuencias. La solicitud también se refiere a usos de los anticuerpos y sus composiciones, en particular, con fines terapéuticos en el campo de las enfermedades cancerosas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18176889 | 2018-06-09 | ||
EP18176888 | 2018-06-09 | ||
EP19159321 | 2019-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP20084864A true ECSP20084864A (es) | 2021-05-31 |
Family
ID=66752128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202084864A ECSP20084864A (es) | 2018-06-09 | 2020-12-30 | Anticuerpos biespecíficos contra dll3-cd3 |
Country Status (21)
Country | Link |
---|---|
US (3) | US11332541B2 (es) |
EP (1) | EP3802598A1 (es) |
JP (2) | JP7133043B2 (es) |
KR (1) | KR20210018311A (es) |
CN (1) | CN112513092A (es) |
AU (1) | AU2019280900A1 (es) |
BR (1) | BR112020022898A2 (es) |
CA (1) | CA3099956A1 (es) |
CL (1) | CL2020003105A1 (es) |
CO (1) | CO2020015172A2 (es) |
CR (1) | CR20200601A (es) |
EC (1) | ECSP20084864A (es) |
IL (1) | IL279235A (es) |
JO (1) | JOP20200313A1 (es) |
MA (1) | MA52742A (es) |
MX (1) | MX2020013348A (es) |
PE (1) | PE20210321A1 (es) |
PH (1) | PH12020552080A1 (es) |
SA (1) | SA520420748B1 (es) |
SG (1) | SG11202011134XA (es) |
WO (1) | WO2019234220A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI817974B (zh) | 2017-12-28 | 2023-10-11 | 日商中外製藥股份有限公司 | 細胞毒性誘導治療劑 |
CN112584860B (zh) | 2018-05-08 | 2024-04-05 | 凡恩世制药(北京)有限公司 | 抗dll3抗体及其用途 |
US20210355197A1 (en) * | 2018-10-22 | 2021-11-18 | International Aids Vaccine Initiative | Anti-hiv antibodies |
TW202128756A (zh) * | 2019-10-02 | 2021-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
AU2021213840A1 (en) * | 2020-01-31 | 2022-09-29 | Gensun Biopharma Inc. | Bispecific T cell engagers |
EP4126969A4 (en) * | 2020-03-31 | 2024-05-29 | Chugai Seiyaku Kabushiki Kaisha | MULTISPECIFIC ANTIGEN-BINDING MOLECULES TARGETING DLL3 AND THEIR USES |
JP2023504675A (ja) | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガンの処置のための結合分子 |
KR20230024904A (ko) * | 2020-05-20 | 2023-02-21 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도 |
CN111551733A (zh) * | 2020-05-29 | 2020-08-18 | 武汉大学 | 定量检测免疫细胞来源细胞外囊泡pd-1含量的方法、elisa试剂盒及使用方法 |
AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
CN117425500A (zh) * | 2021-01-13 | 2024-01-19 | 纪念斯隆凯特琳癌症中心 | 抗dll3抗体-药物缀合物 |
KR20230146521A (ko) * | 2021-01-13 | 2023-10-19 | 메모리얼 슬로안 케터링 캔서 센터 | 항체-피롤로벤조디아제핀 유도체 접합체 |
US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
KR20240050373A (ko) | 2021-09-02 | 2024-04-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 미래의 색값 또는 대응하는 특성을 결정하는 방법 및 이를 위한 장치 |
WO2023116861A1 (zh) | 2021-12-23 | 2023-06-29 | 江苏恒瑞医药股份有限公司 | 抗dll3抗体、其抗体-药物偶联物及其医药用途 |
CN118591564A (zh) * | 2022-02-10 | 2024-09-03 | 上海齐鲁制药研究中心有限公司 | 一种双特异性抗原结合分子及其应用 |
IL314195A (en) | 2022-02-23 | 2024-09-01 | Amgen Inc | Cancer treatment targeting DLL3 |
TW202405004A (zh) * | 2022-06-23 | 2024-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合dll3和cd3的抗原結合分子及其醫藥用途 |
WO2024089006A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
WO2024088991A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
WO2024089008A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
US20240166705A1 (en) | 2022-11-07 | 2024-05-23 | Xencor, Inc. | Il18-fc fusion proteins |
WO2024123965A2 (en) * | 2022-12-08 | 2024-06-13 | Amgen Inc. | Methods for treating dll3-expressing cancer |
WO2024159174A1 (en) * | 2023-01-27 | 2024-08-02 | The United States Goverment As Represented By The Department Of Veterans Affairs | Compositions for treating tauopathies and methods of use thereof |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
GB9012995D0 (en) | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
CA2097060A1 (en) | 1990-12-04 | 1992-06-05 | Peter J. Curtis | Bifunctional antibodies and method of preparing same |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
EP1621554B2 (en) | 1992-08-21 | 2012-08-29 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US20020083888A1 (en) | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
EP1409240B1 (en) | 2001-07-20 | 2012-05-09 | Life Technologies Corporation | Luminescent nanoparticles and methods for their preparation |
KR20060041205A (ko) | 2003-07-01 | 2006-05-11 | 이뮤노메딕스, 인코오포레이티드 | 양특이성 항체들의 다가 담체들 |
US7968542B2 (en) | 2005-07-15 | 2011-06-28 | Nissan Chemical Industries, Ltd. | Thiophene compounds and thrombopoietin receptor activators |
EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
KR101472250B1 (ko) | 2005-10-12 | 2014-12-11 | 모르포시스 아게 | 인간 cd38에 특이적인 완전 인간 hucal gold-유도 치료 항체들의 생성 및 프로파일링 |
CA2633593A1 (en) | 2005-12-16 | 2007-10-04 | Genentech, Inc. | Method for diagnosing, prognosing and treating glioma |
US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
PE20110217A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
TW201100543A (en) * | 2009-05-27 | 2011-01-01 | Hoffmann La Roche | Tri-or tetraspecific antibodies |
MX342623B (es) | 2009-06-26 | 2016-10-06 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
MX2012002565A (es) | 2009-09-01 | 2012-05-29 | Genentech Inc | Purificacion de proteina mejorada a traves de una elucion de proteina a modificada. |
BR112012017051A2 (pt) | 2009-12-23 | 2017-12-05 | Esbatech Alcon Biomed Res Unit | método para diminuir a imunogenicidade |
JP5918540B2 (ja) | 2010-01-29 | 2016-05-18 | 中外製薬株式会社 | 抗dll3抗体 |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
CN103154035B (zh) | 2010-05-27 | 2017-05-10 | 根马布股份公司 | 针对her2的单克隆抗体 |
CA2806252C (en) | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Antibodies with modified isoelectric points |
WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
BR112013023653A2 (pt) | 2011-03-17 | 2016-12-13 | Univ Ramot | anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica |
JP6177231B2 (ja) | 2011-04-20 | 2017-08-09 | ゲンマブ エー/エス | Her2に対する二重特異性抗体 |
WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
MX350074B (es) | 2011-06-23 | 2017-08-25 | Ablynx Nv | Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina. |
MX2014001883A (es) | 2011-08-17 | 2014-05-27 | Glaxo Group Ltd | Proteinas y peptidos modificados. |
CA2850818A1 (en) | 2011-10-11 | 2013-04-18 | Genentech, Inc. | Improved assembly of bispecific antibodies |
HUE044633T2 (hu) | 2011-10-27 | 2019-11-28 | Genmab As | Heterodimer fehérjék elõállítása |
PL2794905T3 (pl) | 2011-12-20 | 2020-11-02 | Medimmune, Llc | Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych |
PE20150090A1 (es) | 2012-02-24 | 2015-02-16 | Stem Centrx Inc | Moduladores y metodos de empleo novedosos referencia cruzada a solicitudes |
SI2838918T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul |
CN104640561A (zh) | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
EP2927321B1 (en) | 2012-11-27 | 2021-02-17 | Ajou University Industry-Academic Cooperation Foundation | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
EP2992010B1 (en) | 2013-04-29 | 2021-03-24 | F.Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
WO2015095392A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
CN106471117A (zh) | 2014-05-06 | 2017-03-01 | 豪夫迈·罗氏有限公司 | 使用哺乳动物细胞产生异多聚体蛋白 |
CA2952540C (en) * | 2014-07-31 | 2022-06-21 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
GB201414823D0 (en) | 2014-08-20 | 2014-10-01 | Argen X Bv | Multispecific antibodies |
UA123624C2 (uk) | 2014-09-03 | 2021-05-05 | Бьорінґер Інґельхайм Інтернаціональ Ґмбх | Сполука, специфічна до іл-23а та фнп-альфа, та її застосування |
EP3842453A1 (en) | 2014-11-06 | 2021-06-30 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and protein a-binding properties |
JP2018519832A (ja) * | 2015-06-30 | 2018-07-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 多重特異的結合タンパク質 |
TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
TWI796283B (zh) * | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
EP3337507A4 (en) * | 2015-08-17 | 2019-04-24 | MacroGenics, Inc. | BISPECIFIC MONOVALENT DIANTIBERS CAPABLE OF BINDING TO B7-H3 AND CD3 AND USES THEREOF |
RS61510B1 (sr) | 2016-05-18 | 2021-03-31 | Boehringer Ingelheim Int | Anti pd-1 i anti-lag3 antitela za lečenje kancera |
SG11202009804RA (en) * | 2018-04-11 | 2020-11-27 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
KR20200083879A (ko) | 2018-12-31 | 2020-07-09 | 삼성디스플레이 주식회사 | 색변환 기판 및 표시 장치 |
-
2019
- 2019-06-07 AU AU2019280900A patent/AU2019280900A1/en active Pending
- 2019-06-07 MX MX2020013348A patent/MX2020013348A/es unknown
- 2019-06-07 CA CA3099956A patent/CA3099956A1/en active Pending
- 2019-06-07 PE PE2020001978A patent/PE20210321A1/es unknown
- 2019-06-07 MA MA052742A patent/MA52742A/fr unknown
- 2019-06-07 CR CR20200601A patent/CR20200601A/es unknown
- 2019-06-07 KR KR1020207036859A patent/KR20210018311A/ko not_active Application Discontinuation
- 2019-06-07 BR BR112020022898-2A patent/BR112020022898A2/pt unknown
- 2019-06-07 JP JP2020568407A patent/JP7133043B2/ja active Active
- 2019-06-07 CN CN201980051335.7A patent/CN112513092A/zh active Pending
- 2019-06-07 WO PCT/EP2019/064942 patent/WO2019234220A1/en unknown
- 2019-06-07 SG SG11202011134XA patent/SG11202011134XA/en unknown
- 2019-06-07 US US16/434,188 patent/US11332541B2/en active Active
- 2019-06-07 JO JOP/2020/0313A patent/JOP20200313A1/ar unknown
- 2019-06-07 EP EP19728454.0A patent/EP3802598A1/en active Pending
-
2020
- 2020-11-30 CL CL2020003105A patent/CL2020003105A1/es unknown
- 2020-12-02 CO CONC2020/0015172A patent/CO2020015172A2/es unknown
- 2020-12-03 PH PH12020552080A patent/PH12020552080A1/en unknown
- 2020-12-06 IL IL279235A patent/IL279235A/en unknown
- 2020-12-08 SA SA520420748A patent/SA520420748B1/ar unknown
- 2020-12-30 EC ECSENADI202084864A patent/ECSP20084864A/es unknown
-
2022
- 2022-03-04 US US17/686,453 patent/US20220251236A1/en active Pending
- 2022-08-26 JP JP2022134954A patent/JP2022180379A/ja active Pending
-
2023
- 2023-06-01 US US18/327,456 patent/US20230295337A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MA52742A (fr) | 2021-04-14 |
SA520420748B1 (ar) | 2023-12-06 |
TW202016151A (zh) | 2020-05-01 |
CR20200601A (es) | 2021-01-26 |
JP2022180379A (ja) | 2022-12-06 |
CA3099956A1 (en) | 2019-12-12 |
PH12020552080A1 (en) | 2021-05-31 |
MX2020013348A (es) | 2021-03-09 |
JOP20200313A1 (ar) | 2020-12-06 |
JP7133043B2 (ja) | 2022-09-07 |
US20190375849A1 (en) | 2019-12-12 |
US20220251236A1 (en) | 2022-08-11 |
US11332541B2 (en) | 2022-05-17 |
BR112020022898A2 (pt) | 2021-02-23 |
IL279235A (en) | 2021-01-31 |
KR20210018311A (ko) | 2021-02-17 |
CN112513092A (zh) | 2021-03-16 |
CL2020003105A1 (es) | 2021-06-11 |
WO2019234220A1 (en) | 2019-12-12 |
US20230295337A1 (en) | 2023-09-21 |
SG11202011134XA (en) | 2020-12-30 |
JP2021526816A (ja) | 2021-10-11 |
PE20210321A1 (es) | 2021-02-16 |
AU2019280900A1 (en) | 2020-11-19 |
EP3802598A1 (en) | 2021-04-14 |
CO2020015172A2 (es) | 2020-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20084864A (es) | Anticuerpos biespecíficos contra dll3-cd3 | |
ECSP20075198A (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos | |
BR112018072986A2 (pt) | anticorpos anti-pd-1 e anti-lag3 para tratamento de câncer | |
CL2018000422A1 (es) | Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos | |
PE20201341A1 (es) | Anticuerpos de union a gprc5d | |
CL2021000131A1 (es) | Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos. | |
MX2021007320A (es) | Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor. | |
CO2017001919A2 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
PE20210289A1 (es) | Anti-cd25 para el agotamiento de celulas tumorales especificas | |
MX2018012757A (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
EA201791554A1 (ru) | Биспецифичные антитела против cd3 и cd20 | |
PE20181303A1 (es) | Compuestos que inhiben eif4a y metodos relacionados a los mismos | |
PE20151410A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t | |
CO2020012347A2 (es) | Anticuerpos anti-hla-g y usos de los mismos. | |
CL2021001628A1 (es) | Anticuerpo humanizado anti-pd-1 humana | |
CO2020009106A2 (es) | Derivados de tiofeno no condensados y sus usos | |
NI202000087A (es) | Anticuerpos ant-tmeff2 monoespecíficos y multiespecíficos y sus usos | |
CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos | |
AR114129A1 (es) | ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS | |
CL2019002735A1 (es) | Anticuerpos que se unen a steap-1. | |
AR117950A1 (es) | Receptores quiméricos de steap1 y composición farmacéutica que los contienen | |
CO2022003053A2 (es) | Proteínas de unión a antígenos | |
AR121013A1 (es) | Anticuerpos anti-cd40 y composiciones | |
AR120095A1 (es) | Proteínas de unión a antígenos | |
AR115311A1 (es) | Anticuerpo biespecífico que específicamente se une a los subdominios iv y ii del dominio extracelular del her2 humano |